ChromoGenics AB (publ) Rights Issue January 2018

Issue amount at full subscription
40,6 MSEK

Subscriptions and warranty commitments
Subscription commitments of approximately 1,0 MSEK and warranty commitments of approximately 32,0 MSEK have been entered into, which corresponds to approximately 81,3% of 40,6 MSEK.

Preference rights and unit rights
Anyone who was registered as a shareholder at the record date January 4th of 2018 has preference rights to subscribe for Units in the Rights Issue and will receive one (1) unit right for each share held. One (1) unit right entitles to subscription of one (1) Unit consisting of each (1) newly issued share and free warrant. In addition, shareholders and other investors are being offered without preferential right to register an interest in subscribing for new shares.

Subscription course
1,75 SEK per United, whereas one (1) Unit consists of one (1) share and one (1) free warrant.

Subscription time
8th – 22th of January 2018

Trade with unit rights
8th – 18th of January 2018

ISIN codes at Nasdaq First North
Share – CHRO SE0009496268
Unit right – UR SE0010739813
Paid subscription Unit – SE0010739821

• Download the information brochure here
• Download the Prospectus here
• Download the application form here
• Download the press release about Prospectus regarding Rights Issue here
• Download the Communiqué from the extra general meeting here
• Download the attachments from the Communiqué from the extra general meeting here
• Download the auditors statement on the Board’s report on significant events in accordance with ch. Section 6 of the Swedish Companies Act (2005 551) here
• Download the press release The Board’s decision about the Rights Issue here

The following documents are available for inspection at the Company’s office (Ullforsgatan 15, 752 28 Uppsala) as well as in electronic form at the Company’s website (www.chromogenics.com):

• Articles of association of ChromoGenics AB (publ)
• Prospectus
• ChromoGenics AB (publ) reviewed financial interim information for the period January-September 2017
• ChromoGenics AB (publ) audited accounts for the financial year of 2016, including the auditor’s report
• ChromoGenics AB (publ) audited accounts for the financial year of 2015, including the auditor’s report

The company’s annual reports have been prepared in accordance with the Annual Accounts Act (1995:1554) and The Swedish Accounting Standards Board’s general advice BFNAR 2012:1 (K3), and has been audited by the Company’s auditor. The audit reports for the annual reports of 2015 and 2016 are found on the last page of each annual report and are incorporated in their entirety by reference and form a part of the Prospectus. The financial interim information for 2017 has been established according to the same principles and regulations. The financial interim information has been reviewed by the Company’s auditor. The Company’s interim information for January – September 2017, including the audit report, is incorporated by reference and forms a part of the Prospectus. Below is a reference to the specific documents and pages:

• The financial interim information for the period January – September 2017. The income statement and balance sheet can be found on pages 9 and 10 in the interim financial information, as well as the audit report on page 7.
• The Company’s annual report for the financial year 2016, the income statement (page 20), balance sheet (pages 21-22), note 16 over changes in equity (page 23), accounting principles and disclosures in notes (pages 25-37) together with the audit report (pages 38-39).
• The Company’s annual report for the financial year 2015, the income statement (page 6), balance sheet (pages 7-8), note 16 over changes in equity (page 20), accounting principles and disclosures in notes (pages 9-22) together with the audit report (last page).